Table 7 2/2 Cancer related traits from the GWAS Catalog v1.0 (release date: 2017-07-31)
Cancer related traits |
|---|
Non-melanoma skin cancer |
Non-small cell lung cancer |
Non-small cell lung cancer (recurrence rate) |
Non-small cell lung cancer (survival) |
Obesity in adult survivors of childhood cancer exposed to cranial radiation |
Obesity in adult survivors of childhood cancer not exposed to cranial radiation |
Oral cavity and pharyngeal cancer |
Oral cavity cancer |
Oropharynx cancer |
Ovarian cancer |
Ovarian cancer in BRCA1 mutation carriers |
Pancreatic cancer |
Plasma androstenedione levels in resected early stage-receptor positive breast cancer |
Plasma estrone conjugates levels in resected early stage estrogen-receptor positive breast cancer |
Plasma estrone levels in resected estrogen-receptor positive breast cancer |
Platinum-induced myelosuppression in non-small cell lung cancer |
Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab) |
Progression free survival in metastatic colorectal cancer (treatment interaction) |
Prostate cancer |
Prostate cancer (early onset) |
Prostate cancer (interaction) |
Prostate cancer (survival) |
Prostate cancer aggressiveness |
Pulmonary function |
Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50) |
Response to carboplatin and paclitaxel in ovarian cancer (MTT IC50) |
Response to carboplatin in ovarian cancer (MTT IC50) |
Response to chemotherapy in breast cancer (hypertension) (bevacizumab) |
Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab) |
Response to gemcitabine in pancreatic cancer |
Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer |
Response to irinotecan in non-small-cell lung cancer |
Response to paclitaxel in ovarian cancer (Caspase 3/7 EC50) |
Response to paclitaxel in ovarian cancer (MTT IC50) |
Response to Pazopanib in cancer (hepatotoxicity) |
Response to platinum-based agents |
Response to platinum-based chemotherapy (carboplatin) |
Response to platinum-based chemotherapy (cisplatin) |
Response to platinum-based chemotherapy in non-small-cell lung cancer |
Response to platinum-based neoadjuvant chemotherapy in cervical cancer |
Response to radiotherapy in cancer (late toxicity) |
Response to radiotherapy in prostate cancer (overall toxicity) |
Response to radiotherapy in prostate cancer (toxicity |
Response to radiotherapy in prostate cancer (toxicity |
Response to radiotherapy in prostate cancer (toxicity |
Response to radiotherapy in prostate cancer (toxicity) |
Response to tamoxifen in breast cancer |
Small-cell lung cancer (survival) |
Survival in colon cancer |
Survival in colorectal cancer |
Survival in colorectal cancer (distant metastatic) |
Survival in colorectal cancer (non-distant metastatic) |
Survival in endocrine treated breast cancer (estrogen-receptor positive) |
Survival in head and neck cancer |
Survival in microsatellite instability low/stable colorectal cancer |
Survival in rectal cancer |
Testicular cancer |
Testicular germ cell cancer |
Thyroid cancer |
Thyroid cancer (Papillary |
Urinary bladder cancer |
Urinary symptoms in response to radiotherapy in prostate cancer |